Clinical Research of Compound Zhebei Granules for Increasing the Therapeutic Effect of Chemotherapy in Refractory Acute Leukemia Patients

• Published in: Journal of traditional Chinese medicine Vol. 29; no. 3; pp. 190 - 194
• Main Author: 卢殿荣 李冬云 陈信义 叶霈智 田邵丹
• Format: Journal Article
• Language: English
• Published: China 01.09.2009
• Subjects: Acute Disease; Adult; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Humans; Leukemia - drug therapy; Leukemia, Myeloid - drug therapy; Male; Medicine, Chinese Traditional; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Remission Induction; Treatment Outcome; Young Adult; 临床; 化疗; 复方; 急性白血病; 控制项目; 浙北; 疗效观察; 颗粒
• ISSN: 0255-2922
• DOI: 10.1016/S0254-6272(09)60063-7

Objective： To observe the effects of Compound Zhebei Granules （复方浙贝颗粒 CZG） in chemotherapy for refractory acute leukemia. Method： Using a randomized, double-blind and multi-central concurrent control clinical research project, the patients conformed with the diagnostic criteria, according to the drug randomized method, were divided into a CZG group and a control group. The patients of the two groups respectively took the observation drug or a placebo 3 days before chemotherapy, and the therapeutic effects were evaluated after one course of chemotherapy. According to the clinical research project, 137 patients were enrolled, including 71 cases in the CZG group and 66 cases in the control group. Results： The clinical complete remission （CR） rate was 42.3% in the CZG group with a total effective rate of 73.2%, and it was 25.8% in the control group with a total effective rate of 53.0%, showing a statistically significant difference between the two groups （P〈0.05）. Conclusion： CZG can increase the clinical remission rate for refractory acute leukemia during chemotherapy.